NASDAQ:VERU Veru - VERU Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Veru Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.42 -0.17 (-10.69%) (As of 03/22/2023 02:09 PM ET) Add Compare Share Share Today's Range$1.36▼$1.5850-Day Range$1.59▼$6.4152-Week Range$1.36▼$24.55Volume3.71 million shsAverage Volume2.55 million shsMarket Capitalization$114.54 millionP/E RatioN/ADividend YieldN/APrice Target$28.33 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Veru MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,895.3% Upside$28.33 Price TargetShort InterestBearish22.84% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.42Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.28) to ($0.78) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.08 out of 5 starsMedical Sector414th out of 983 stocksPharmaceutical Preparations Industry196th out of 478 stocks 3.5 Analyst's Opinion Consensus RatingVeru has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $28.33, Veru has a forecasted upside of 1,895.3% from its current price of $1.42.Amount of Analyst CoverageVeru has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted22.84% of the float of Veru has been sold short.Short Interest Ratio / Days to CoverVeru has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Veru has recently decreased by 0.34%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldVeru does not currently pay a dividend.Dividend GrowthVeru does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VERU. Previous Next 2.5 News and Social Media Coverage News SentimentVeru has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Veru this week, compared to 6 articles on an average week.Search Interest66 people have searched for VERU on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days.MarketBeat Follows14 people have added Veru to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Veru insiders have not sold or bought any company stock.Percentage Held by Insiders23.90% of the stock of Veru is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions48.87% of the stock of Veru is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Veru are expected to grow in the coming year, from ($1.28) to ($0.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Veru is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Veru is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVeru has a P/B Ratio of 1.41. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Veru (NASDAQ:VERU) StockVeru, Inc. is an oncology biopharmaceutical company, which engages in developing novel medicines for the management of prostate cancer and breast cancer. Its prostate cancer drug candidates include: VERU-111, an oral alpha and beta tubulin inhibitor, which is in a Phase 2 clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer, VERU-100, a novel, proprietary, GnRH antagonist peptide drug formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer, and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist being developed to treat hot flashes, a common side effect caused by ADT. The firm's breast cancer drug candidates include: Enobosarm, an oral, new chemical entity, selective androgen receptor agonist that targets the androgen receptor in AR+/ER+/HER2-hormone sensitive metastatic breast cancer without unwanted virilizing side effects, and VERU 111 for triple negative metastatic breast cancer that has become resistant to taxane IV chemotherapy. It is also advancing the new drug formulation TADFYN, tadalafil and finRead More Receive VERU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Veru and its competitors with MarketBeat's FREE daily newsletter. Email Address VERU Stock News HeadlinesMarch 17, 2023 | americanbankingnews.comOppenheimer Research Analysts Boost Earnings Estimates for Veru Inc. (NASDAQ:VERU)March 15, 2023 | americanbankingnews.comOppenheimer Cuts Veru (NASDAQ:VERU) Price Target to $9.00March 22, 2023 | Press Reach (Ad)Stock Market UpdateThis stock is taking America by storm. Find out why it's trending right now. March 15, 2023 | americanbankingnews.comVeru Inc. (NASDAQ:VERU) Given Consensus Rating of "Buy" by AnalystsMarch 14, 2023 | finance.yahoo.comUPDATE 1-Veru to proceed with late-stage study of COVID pill despite FDA snubMarch 7, 2023 | finance.yahoo.comVeru to Present at the Oppenheimer 33rd Annual Healthcare ConferenceMarch 3, 2023 | investorplace.comWhy Is Veru (VERU) Stock Down 37% Today?March 2, 2023 | finance.yahoo.comVeru Provides FDA Update on Request for Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for ARDSMarch 22, 2023 | Press Reach (Ad)Stock Market UpdateThis stock is taking America by storm. Find out why it's trending right now. February 14, 2023 | finance.yahoo.comVeru Inc. (NASDAQ:VERU) Shares Could Be 50% Below Their Intrinsic Value EstimateFebruary 10, 2023 | finance.yahoo.comVeru Inc. (NASDAQ:VERU) Q1 2023 Earnings Call TranscriptFebruary 7, 2023 | benzinga.comFinal Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Veru Inc. (VERU) Investors of Class Action and to Actively ParticipateJanuary 26, 2023 | finance.yahoo.comVeru to Report Fiscal 2023 First Quarter Financial Results on February 9, 2023January 21, 2023 | benzinga.comROSEN, LEADING INVESTOR COUNSEL, Encourages Veru, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action– VERUJanuary 17, 2023 | finance.yahoo.comThose who invested in Veru (NASDAQ:VERU) five years ago are up 364%January 10, 2023 | finance.yahoo.comVeru Announces Appointment of Dr. David D. Ho as Chairman of its Infectious Disease Scientific Advisory BoardJanuary 6, 2023 | finance.yahoo.comIf You Invested $1,000 in Veru in 2020, This Is How Much You Would Have TodayJanuary 4, 2023 | benzinga.comVeru Inc. Sued By Block & Leviton LLP for Securities Law ViolationsJanuary 2, 2023 | wsj.comSHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Veru Inc. with Losses of $100,000 to Contact the FirmDecember 20, 2022 | markets.businessinsider.comINVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Veru Inc. with Losses of $100,000 to Contact the FirmDecember 10, 2022 | finance.yahoo.comIs There any Hope for Veru Stock?December 8, 2022 | finance.yahoo.comVeru Inc. (NASDAQ:VERU) Q4 2022 Earnings Call TranscriptDecember 7, 2022 | finance.yahoo.comVeru Full Year 2022 Earnings: Misses ExpectationsDecember 5, 2022 | finance.yahoo.comEdited Transcript of VERU.OQ earnings conference call or presentation 5-Dec-22 1:00pm GMTDecember 5, 2022 | finance.yahoo.comVeru Inc. (VERU) Reports Q4 Loss, Lags Revenue EstimatesDecember 2, 2022 | finance.yahoo.comIs Veru a Buy?November 28, 2022 | finance.yahoo.comVeru to Report Fiscal 2022 Fourth Quarter and Full Year Financial Results on December 5, 2022See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive VERU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Veru and its competitors with MarketBeat's FREE daily newsletter. Email Address VERU Company Calendar Last Earnings12/02/2021Today3/22/2023Next Earnings (Estimated)5/11/2023Fiscal Year End9/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryPersonal Products SectorMedical Current SymbolNASDAQ:VERU CUSIP31446210 CIK863894 Webwww.veruhealthcare.com Phone(305) 509-6897Fax312-595-9122Employees252Year FoundedN/APrice Target and Rating Average Stock Price Forecast$28.33 High Stock Price Forecast$55.00 Low Stock Price Forecast$9.00 Forecasted Upside/Downside+1,682.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-83,780,000.00 Net Margins-412.01% Pretax Margin-411.82% Return on Equity-119.37% Return on Assets-79.71% Debt Debt-to-Equity RatioN/A Current Ratio1.82 Quick Ratio1.60 Sales & Book Value Annual Sales$39.35 million Price / Sales3.26 Cash FlowN/A Price / Cash FlowN/A Book Value$1.01 per share Price / Book1.57Miscellaneous Outstanding Shares80,660,000Free Float61,380,000Market Cap$128.25 million OptionableOptionable Beta-0.15 Key ExecutivesMitchell Shuster SteinerChairman, President & Chief Executive OfficerMichele GrecoChief Financial & Administrative OfficerRobert H. GetzenbergExecutive Vice President-Medical AffairsDomingo RodriguezExecutive Vice President-Clinical OperationsK. Gary BarnetteChief Scientific OfficerKey CompetitorsNature's Sunshine ProductsNASDAQ:NATRLifecore BiomedicalNASDAQ:LFCROvid TherapeuticsNASDAQ:OVIDY-mAbs TherapeuticsNASDAQ:YMABCitius PharmaceuticalsNASDAQ:CTXRView All CompetitorsInsiders & InstitutionsParallax Volatility Advisers L.P.Sold 60,200 shares on 2/27/2023Ownership: 0.000%State of Wisconsin Investment BoardSold 3,991 shares on 2/15/2023Ownership: 0.074%Mariner LLCBought 3,158 shares on 2/15/2023Ownership: 0.042%Money Concepts Capital CorpBought 18,000 shares on 2/15/2023Ownership: 0.022%Centiva Capital LPSold 11,600 shares on 2/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions VERU Stock - Frequently Asked Questions Should I buy or sell Veru stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veru in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VERU shares. View VERU analyst ratings or view top-rated stocks. What is Veru's stock price forecast for 2023? 5 Wall Street research analysts have issued 12-month price targets for Veru's shares. Their VERU share price forecasts range from $9.00 to $55.00. On average, they predict the company's stock price to reach $28.33 in the next year. This suggests a possible upside of 1,682.0% from the stock's current price. View analysts price targets for VERU or view top-rated stocks among Wall Street analysts. How have VERU shares performed in 2023? Veru's stock was trading at $5.28 at the beginning of 2023. Since then, VERU stock has decreased by 69.9% and is now trading at $1.59. View the best growth stocks for 2023 here. When is Veru's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023. View our VERU earnings forecast. How were Veru's earnings last quarter? Veru Inc. (NASDAQ:VERU) posted its quarterly earnings data on Thursday, December, 2nd. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.04. The firm had revenue of $15.65 million for the quarter, compared to analyst estimates of $18.26 million. Veru had a negative trailing twelve-month return on equity of 119.37% and a negative net margin of 412.01%. During the same period in the prior year, the business posted ($0.01) earnings per share. What ETFs hold Veru's stock? ETFs with the largest weight of Veru (NASDAQ:VERU) stock in their portfolio include Fidelity MSCI Consumer Staples Index ETF (FSTA), Vanguard Consumer Staples ETF (VDC) and Carbon Collective Climate Solutions U.S. Equity ETF (CCSO) and What other stocks do shareholders of Veru own? Based on aggregate information from My MarketBeat watchlists, some companies that other Veru investors own include Kadmon (KDMN), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Corbus Pharmaceuticals (CRBP), Matinas BioPharma (MTNB), Organigram (OGI), Vaxart (VXRT), Rigel Pharmaceuticals (RIGL), SCYNEXIS (SCYX) and VBI Vaccines (VBIV). What is Veru's stock symbol? Veru trades on the NASDAQ under the ticker symbol "VERU." Who are Veru's major shareholders? Veru's stock is owned by many different institutional and retail investors. Top institutional investors include Morgan Stanley (9.05%), Geode Capital Management LLC (1.37%), Millennium Management LLC (0.76%), Susquehanna International Group LLP (0.00%), Charles Schwab Investment Management Inc. (0.52%) and Boxer Capital LLC (0.43%). Insiders that own company stock include Harry Fisch, K Gary Barnette, Lucy Lu, Mario Eisenberger, Michele Greco and Mitchell Shuster Steiner. View institutional ownership trends. How do I buy shares of Veru? Shares of VERU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Veru's stock price today? One share of VERU stock can currently be purchased for approximately $1.59. How much money does Veru make? Veru (NASDAQ:VERU) has a market capitalization of $128.25 million and generates $39.35 million in revenue each year. The company earns $-83,780,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis. How many employees does Veru have? The company employs 252 workers across the globe. How can I contact Veru? Veru's mailing address is 48 NW 25th Street Suite 102, Miami FL, 33127. The official website for the company is www.veruhealthcare.com. The company can be reached via phone at (305) 509-6897, via email at veruinvestor@verupharma.com, or via fax at 312-595-9122. This page (NASDAQ:VERU) was last updated on 3/22/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.